

Medigen Biotechnology Corp. (3176 MEDIGEN)					
SEQ_NO	1	Date of announcement	2023/12/08	Time of announcement	18:51:44
Subject	The cumulative securities disposed by the Company have reached the announcement threshold				
Date of events	2023/12/08	To which item it meets	paragraph 20		
Statement	<p>1. Name of the securities: 6547 Medigen Vaccine and Biologics Corp.</p> <p>2. Trading date: 2022/7/8 ~ 2023/12/8</p> <p>3. Amount, unit price, and total monetary amount of the transaction: Volume: 3,460,000 shares Unit price: NTD 80.54 Total monetary amount : NTD 278,660,300</p> <p>4. Gain (or loss) through disposal (not applicable in case of acquisition of securities): Gain NTD 218,598,627 (This realized gain is listed under capital surplus - the difference between the acquisition or disposal of subsidiary equity and book value, without affecting the current profit and loss)</p> <p>5. Relationship with the underlying company of the trade: Subsidiary of the Company</p> <p>6. Current cumulative amount held, monetary value, and shareholding percentage of cumulative holdings of the securities being traded (including the current trade), and status of any restriction of rights (e.g., pledges): Cumulative amount held: 62,508,844 shares (deducting the disposed shares) Cumulative monetary value : NTD 822,7785,026 Cumulative shareholding percentage : 19.02% Restriction of rights : number of shares pledged 13,900,000</p> <p>7. Current ratio of securities investment (including the current trade) to the total assets and equity attributable to owners of parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as of the present, as listed in the Regulations Governing the Acquisition and Disposal of Assets by Public Companies: Ratio of securities investment to the total assets : 27.79% Ratio of securities investment to the shareholder's equity : 37.50 %</p>				

	<p>Working capital : NTD 131,011 thousand</p> <p>8. Purpose of the acquisition or disposal: To increase working capital</p> <p>9. Whether the directors expressed any objection to the current transaction: No</p> <p>10. Whether the counterparty of the current transaction is a related party: No</p> <p>11. Trading counterparty and its relationship to the Company: NA</p> <p>12. Date of the board of directors' resolution: 2020/5/11 and 2022/8/9</p> <p>13. Date of ratification by supervisors or approval by the audit committee: NA</p> <p>14. Any other matters that need to be specified: None</p>
--	---